The shortage is entirely arbitrary, and only exists in the US.
We had a significant increase in ADHD diagnosis during the pandemic, because telehealth is much more approachable for people with untreated ADHD.
Despite that increase, the DEA refused to increase the arbitrary limit for how much Adderall can be manufactured in the US. So we have an entirely avoidable shortage on our hands.
> We had a significant increase in ADHD diagnosis during the pandemic, because telehealth is much more approachable for people with untreated ADHD.
And, in typical fashion, the DEA responds to the problem in nearly the worst way possible: they announced new regulations to stop telehealth providers from writing new prescriptions for ADHD meds. I suppose this keeps the shortage from getting worse, but that’s about it.
They aren’t new regulations, its the ending of the temporary suspension of the old regulations which was premised on the pandemic state of emergency, which has ended.
Its bad because the pre-existing rules were bad and should have been changed instead of merely suspended based on the pandemic.
We had a significant increase in ADHD diagnosis during the pandemic, because telehealth is much more approachable for people with untreated ADHD.
Despite that increase, the DEA refused to increase the arbitrary limit for how much Adderall can be manufactured in the US. So we have an entirely avoidable shortage on our hands.